Live Breaking News & Updates on Treatment Emergent Adverse Events Considered Mild|Page 1

Stay updated with breaking news from Treatment emergent adverse events considered mild. Get real-time updates on events, politics, business, and more. Visit us for reliable news and exclusive interviews.

Viking Therapeutics Announces Positive Top-Line Results from Phase 2 VENTURE Trial of Dual GLP-1/GIP Receptor Agonist VK2735 in Patients with Obesity

Study Achieves Primary and all Secondary Endpoints, Demonstrating Statistically Significant Reductions in Body Weight at all Doses as Compared to Placebo
Up to 13.1% Placebo-Adjusted Mean Weight. ....

Drug Administration , Ligand Pharmaceuticals Incorporated , Therapeutics Inc , Study Achieves Primary , Secondary Endpoints , Body Weight , Placebo Adjusted Mean Weight Loss , From Baseline , Observed After , Week Study , Treatment Emergent Adverse Events Considered Mild , Call Scheduled , Viking Therapeutics , Body Weight Following , Once Weekly Dosing , Common Gastrointestinal , Ligand Pharmaceuticals ,